A case series of morbid COPD exacerbations during immune checkpoint inhibitor therapy in cancer patients

BACKGROUND: Immune checkpoint inhibitor therapy is rapidly becoming front line adjuvant or primary therapy in a number of solid cancer types. Since many of these cancers are a result of tobacco smoking, a large number of these patients will have underlying comorbid conditions attributed to smoking s...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, Viswam S., Eaton, Keith, McGarry Houghton, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566897/
https://www.ncbi.nlm.nih.gov/pubmed/34760616
http://dx.doi.org/10.1016/j.rmcr.2021.101541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566897/
https://www.ncbi.nlm.nih.gov/pubmed/34760616
http://dx.doi.org/10.1016/j.rmcr.2021.101541

Ejemplares similares